'Next Generation' cancer treatment ready for clinical trials

May 18, 2012

(Medical Xpress) -- A new class of anti-cancer drugs which control the growth and spread of cancers and do so with minimal side effects is being developed by researchers at the University of Sydney.

"These new agents attack a fundamental characteristic of while leaving normal cells alone," said Professor Des Richardson, from the Bosch Institute in Sydney Medical School.

"They work by binding the iron in , preventing them from growing. We believe they have the potential to be an effective new strategy, to be 'next generation' drugs, for a range of cancers including highly aggressive .

Because they do not act on non-cancerous cells these new agents dramatically reduce a range of distressing side effects familiar to people undergoing cancer treatments such as chemotherapy and radiotherapy.

Professor Richardson is the head of the and Chelation Program at the University and has been conducting research in this area since the early 1990s.

The latest research on the chelators is led by post-doctoral researcher and NHMRC Early Career Fellow, Dr. Zaklina Kovacevic.

In the Journal of Biological Chemistry, published today, the researchers outline how these new agents increase the levels of a molecule (NDRG1) which inhibits the spread of cancer, including prostate and colon cancers.

"Together with a recent article in the journal, Antioxidants and Redox Signaling, these studies advance our knowledge of cancer cell biology and how we can target specific molecules to stop cancer progressing," Dr. Kovacevic said.

Professor Richardson is currently in advanced discussions on a licensing deal with an American company for developing the compound to the stage of clinical trials.

"This will present a significant step forward in the fight against cancer and provide cancer sufferers new hope for a better outcome," Professor Richardson said.

"It is a difficult step to go from the often quoted bench to bedside, but it has been greatly helped by the Bosch Institute's Translational Grants program, and by an NHMRC Development Grant."

The Executive Director of the Bosch Institute, Professor Jonathan Stone stated: "For anyone who has been through, or cared for a cancer sufferer through, the purgatory of chemotherapy, the prospect of anti-cancer drugs which are broadly effective but with few side effects is immensely welcome."

Explore further: Match your treatment to your cancer

Related Stories

Match your treatment to your cancer

June 30, 2011
(Medical Xpress) -- New research has uncovered why certain cancers don’t respond to conventional chemotherapy, highlighting the need to match treatments to cancers better.

Silencing a deadly conversation in breast cancer

June 2, 2011
While it is already known that breast cancer cells create the conditions for their own survival by communicating their needs to the healthy cells that surround them, Australian researchers have identified a new way of turning ...

Novel drug combination offers therapeutic promise for hard-to-treat cancers

September 12, 2011
Researchers at Brigham and Women's Hospital (BWH) have identified a new combination of targeted therapies that, together, may treat two aggressive tumor types that until now have not had effective treatments. These findings ...

Mechanism of action behind novel cancer agents targeting tumor cell metabolism discovered

July 26, 2011
(Medical Xpress) -- The discovery of the mechanism of action behind a novel class of anticancer drugs designed to disrupt cancer cell mitochondrial metabolism may be a major step toward furthering clinical trials of the agents. ...

Cell discovery strengthens quest for cancer treatments

February 13, 2012
Fresh insights into how our cells multiply could help scientists develop drugs to treat cancer.

New agents show promise for treating aggressive breast cancers

July 18, 2011
Some of the most aggressive forms of breast cancer are more vulnerable to chemotherapy when it is combined with a new class of anti-cancer agent, researchers from the Walter and Eliza Hall Institute have shown.

Recommended for you

Researchers develop test that can diagnose two cancer types

December 12, 2017
A blood test using infrared spectroscopy can be used to diagnose two types of cancer, lymphoma and melanoma, according to a study led by Georgia State University.

Atoh1, a potential Achilles' heel of Sonic Hedgehog medulloblastoma

December 12, 2017
Medulloblastoma is the most common type of solid brain tumor in children. Current treatments offer limited success and may leave patients with severe neurological side effects, including psychiatric disorders, growth retardation ...

Cancer-causing mutation suppresses immune system around tumours

December 12, 2017
Mutations in 'Ras' genes, which drive 25% of human cancers by causing tumour cells to grow, multiply and spread, can also protect cancer cells from the immune system, finds a new study from the Francis Crick Institute and ...

Drug suppresses spread of breast cancer caused by stem-like cells

December 12, 2017
Rare stem-like tumor cells play a critical role in the spread of breast cancer, but a vulnerability in the pathway that powers them offers a strategy to target these cells using existing drugs before metastatic disease occurs, ...

MRI scans predict patients' ability to fight the spread of cancer

December 12, 2017
A simple, non-invasive procedure that can indicate how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy has been developed by researchers in Liverpool.

A new weapon against bone metastasis? Team develops antibody to fight cancer

December 11, 2017
In the ongoing battle between cancer and modern medicine, some therapeutic agents, while effective, can bring undesirable or even dangerous side effects. "Chemo saves lives and improves survival, but it could work much better ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.